secwatch.observer — SEC 8-K summary
======================================

Issuer:     LABCORP HOLDINGS INC. (LH)
CIK:        0000920148
Form:       8-K
Filed at:   2023-06-07T23:59:59+00:00
Accession:  0000920148-23-000040
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Labcorp appoints Dr. Paul Rothman to Board of Directors
-------------------------------------------------------

- Dr. Rothman appointed as independent director effective June 6, 2023, expanding board to 12 members (11 independent).
- Rothman recently retired as CEO of Johns Hopkins Medicine, a $9B academic medical enterprise, after a decade of service.
- He is a rheumatologist and molecular immunologist with leadership roles at Columbia University and University of Iowa.
- Rothman currently serves on the boards of Merck & Co. and King Faisal Specialist Hospital and Research Center.
- Compensation follows Labcorp's standard director compensation program as described in the March 2023 proxy statement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/920148/000092014823000040/0000920148-23-000040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/920148/000092014823000040/lh-20230605.htm
  HTML page:      https://secwatch.observer/filing/0000920148-23-000040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer